- Extendicare’s third-quarter revenue reached C$440.3 million, which is a 23% increase compared to the previous year, outperforming the estimated C$418.5 million.
- The company’s adjusted EBITDA rose to C$50.8 million, marking a 41% year-over-year growth, surpassing the forecast of C$39 million.
- Adjusted Funds From Operations (AFFO) per share increased to C$0.345, up from C$0.25 in the prior year.
- Dr. Michael Guerriere, President and CEO, stated that the quarter reflects strong performance due to margin improvements across all segments and the full impact of recent acquisitions.
- Home health care volumes saw an almost 25% rise from the previous year, driven by 13% organic growth and the acquisition of Closing the Gap.
- The investment community’s sentiment included 5 buy ratings, 3 hold ratings, and no sell ratings on Extendicare shares.
A look at Extendicare Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 5 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Extendicare Inc. provides post-acute and long-term senior care services, operating a network of health care centers offering skilled nursing care, rehabilitative therapies, and home health care services. The company’s overall outlook, as per Smartkarma Smart Scores, indicates a positive long-term future. With a strong emphasis on growth, scoring a 5 in this area, Extendicare Inc. is well-positioned to expand and develop its services over time. Additionally, the company’s momentum, resilience, and dividend scores are also favorable, pointing towards stability and potential returns for investors. Although the value score is moderate at 2, the favorable ratings in other areas suggest a promising future for Extendicare Inc.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
